Published on 31 Mar 2022 on Simply Wall St. via Yahoo Finance
ReShape Lifesciences Inc. (NASDAQ:RSLS) missed earnings with its latest full-year results, disappointing overly-optimistic forecasters. Revenues missed expectations somewhat, coming in at US$14m, but statutory earnings fell catastrophically short, with a loss of US$5.00 some 72% larger than what the analysts had predicted. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
See our latest analysis for ReShape Lifesciences
earnings-and-revenue-growth